T he incidence of thyroid cancer is increasing at approximately 3.0% to 5.3% per year, and mortality is decreasing. 1 However, 10% to 15% of thyroid cancer is locally advanced and is associated with increased mortality, locoregional recurrence, and distant metastases. 2, 3 Though surgery remains the primary treatment modality in these patients, adjuvant treatment aims to address any remaining gross or microscopic residual disease. Radioactive iodine (RAI) is a well-accepted modality of adjuvant therapy able to address both local and distant sites. 4, 5 Locoregional control has also been observed to be improved in patients undergoing external beam radiotherapy (EBRT). [6] [7] [8] These data are based on single institution retrospective studies that are subject to selection bias which may result in baseline differences between treatment groups confounding these outcomes. Reflecting the available evidence, the 2015 American Thyroid Association differentiated thyroid cancer management guidelines states that the role of EBRT remains controversial. 4 According to the 7th Edition of the American Joint Committee on Cancer Staging Manual, 9 locally advanced differentiated thyroid cancer, or T4a/b classification, demonstrate tumor extension to tissues outside the thyroid capsule. This extension can range from minimal tumor extension into the recurrent laryngeal nerve, to gross intraluminal disease in the trachea. Extent and location of invasion has been demonstrated to confer differences in disease outcome. 10 Therefore, understanding the different presentations of gross extension may be important in determining adjuvant treatment protocols. Unfortunately, studies investigating the effectiveness of adjuvant treatment often group all patients with locally advanced disease into a single cohort. Therefore, we aim to describe the role of RAI alone compared with combined therapy with RAI and EBRT in patients with T4a differentiated thyroid cancer, as well as characterize differences in disease outcome according to the location and extent of local invasion.
Methods
Institutional review board approval was obtained and informed consent was waived owing to the retrospective nature of this study. One hundred fifteen of 2581 patients treated surgically for differentiated thyroid cancer at the University of Texas MD Anderson Cancer Center from January 2000 to December 2015 were pathologically diagnosed with a T4a-classified tumor based on the 7th Edition of the American Joint Committee on Cancer Staging Manual. 9 Patients were eligible for inclusion if they were 18 years or older, had more than 1 month of follow-up, and had no other diagnosis of head and neck cancer. Those presenting with recurrent or persistent disease, or undergoing treatment other than primary surgery, were excluded from this study. All eligible patients underwent discussion by a multidisciplinary team to determine recommendation for adjuvant therapy. Twenty-seven patients with T4a tumors undergoing EBRT only or no adjuvant therapy were excluded from the analysis. The majority of these excluded patients received treatment not in keeping with the multidisciplinary recommendations. A total of 88 patients met all inclusion and exclusion criteria. Baseline demographic data were obtained (age, sex, and race), staging, and pathologic data (morphology, lymphovascular invasion, and microscopic perineural invasion) were collected. Location and extent of extrathyroidal extension was determined by presence of tumor invading the recurrent laryngeal nerve (RLN), esophagus, and trachea at the time of surgery.
Patients were divided into exposure groups based on adjuvant treatment received following surgery: (1) radioactive iodine (RAI) alone, or (2) RAI and EBRT. Reasons for receipt of a certain adjuvant treatment regimen were recorded for each treatment category. Because patients received adjuvant therapy based on multidisciplinary decision, reasons for adjuvant therapy were consistent within the institution. Indications for treatment with RAI alone in T4a tumors were invasion into the RLN only or minimal invasion into the tracheal perichondrium and/or esophageal muscularis requiring shave resection only. Patients demonstrating significant soft tissue extension, defined as significant invasion into soft tissue and visceral structures including intraluminal disease, were recommended to undergo both RAI and EBRT.
The primary outcome measure was disease-free survival (DFS). This was defined as time from initial surgery for thyroid malignancy to time of recurrence or death from any cause. Overall survival (OS), time from initial surgery to death from any cause, and disease-specific survival (DSS), time from initial surgery to death from disease, were also calculated. Recurrence rate was determined using locoregional failure (LRF), which was defined as the time from initial surgery to locoregional recurrence, and distant metastatic failure, which was defined as the time from initial surgery to distant metastatic disease detection. Treatment response was assessed approximately 6 months from end of treatment according to the response categories in the 2015 American Thyroid Association Management Guidelines. 4 Patients were considered to have structurally incomplete response if there was radiographic evidence of disease; biochemically incomplete
Key Points
Question What is the role of radioactive iodine with or without external beam radiotherapy in patients with locally advanced differentiated thyroid cancer initially treated with surgery?
Findings In this retrospective cohort study, 5-year disease free survival was 43% in patients undergoing radioactive iodine treatment alone, and 57% in patients undergoing radioactive iodine treatment and external beam radiotherapy, for a difference in survival of 14%. Characteristics associated with poor disease-free survival were increasing age and presence of esophageal invasion. test, wherever appropriate. Owing to the selective study cohort, propensity score matching was not completed to prevent further restriction of the sample size. However, propensity score analysis was completed to compare propensity scores between exposure groups to explore the possibility of selection bias. Variables statistically different between groups and known clinical indicators were used as disease covariates and propensity score was calculated using a logistic regression model. The Kaplan-Meier method was used for all survival analyses and compared with the log-rank test. Survival was compared according to exposure group. The Cox proportional hazards models was used for univariate and multivariate analysis. All variables with P value less than .10 in the univariate analysis were included in the multivariate model. All tests were 2-tailed and α was set to 0.05 for significance. All statistical analysis was completed using SAS JMP Pro version 12.1.0 (SAS Institute).
Meaning

Results
Of the 88 included patients, 44 patients (50%) underwent RAI alone, and 44 patients (50%) underwent both EBRT and RAI. Baseline characteristics for all patients by exposure group are described in detail in Table 1 and were not different between groups. Therefore, known clinical indicators for EBRT (pathologic N classification, extracapsular spread, and margin status) were used for propensity score calculation. The extent of surgery by exposure groups is summarized in Table 2 . In total, all patients had complete resection of the thyroid, with 87 patients (99%) undergoing total thyroidectomy and 1 patient (1%) who underwent lobectomy with completion hemithyroidectomy. In the 61 patients who underwent lateral neck dissection, 59 patients (97%) had clinical lateral neck disease (cN1b). Of the 2 remaining patients, 1 patient had the lateral neck dissection owing to need for a total laryngectomy, and 1 owing to direct extension of the tumor to the lateral neck. In patients undergoing en bloc resection of tracheal ring(s), treatment with both RAI and EBRT was statistically significantly more likely than treatment with RAI alone (effect size = −0.68; 95% CI, −0.83 to −0.38).
Survival and Treatment Response According to Adjuvant Treatment
Overall, 5-year DFS for included patients was 52% (95% CI, 39% to 63%). In those undergoing treatment with RAI alone, 5-year DFS was 43% (95% CI, 23% to 61%), and 57% (95% CI, 40% to 71%) in those undergoing both RAI and EBRT (effect size = 14%; 95% CI, −7% to 33%) ( Figure 1A) . Five-year OS and DSS were 76% (95% CI, 53% to 89%) and 89% (95% CI, 68% to 97%), respectively, in those undergoing RAI alone, and 79% (95% CI, 61% to 89%) and 86% (95% CI, 68% to 94%), respectively, in those undergoing both RAI and EBRT ( Figure 2B and C). Comparison between exposure groups demonstrated no difference in OS (effect size = 5%; 95% CI, −13% to 22%) or DSS (effect size = −2%; 95% CI, −17% to 12%). Of note, patients excluded owing to undergoing EBRT alone did not have significantly different DFS, OS, or DSS compared with included patients.
Treatment response is summarized in eTable 2 in the Supplement. Treatment response did not differ between patients undergoing RAI and EBRT and those undergoing RAI alone at 6 months. Most patients were found to have structurally incomplete response. However, this difference did not reach statistical significance between exposure groups (effect size = 20%; 95% CI, −0.2% to 39.0%).
Locoregional Failure
Locoregional recurrence was detected in 11 patients (13%): 9 patients (82%) had undergone RAI alone, and 2 (18%) had undergone both RAI and EBRT. Ten patients had recurrence in the thyroid bed, 1 in the lateral neck, and 2 in the retropharynx, which includes 2 patients who had recurrence in both the thyroid bed and lateral neck and/or retropharynx. Among the 11 patients who developed recurrence, 6 (55%) were observed with no further treatment. Of the remaining 5 patients, 3 underwent surgical resection of the recurrence, 1 underwent a second dose of RAI, and 1 patient who had been previously treated with RAI alone underwent EBRT. Fiveyear LRF was 34% (95% CI, 18% to 58%) in those undergoing RAI alone, and 3% (95% CI, 4% to 17%) in those undergoing both RAI and EBRT (effect size = −32%; 95% CI, −47 to −16%) (Figure 2A) .
A post hoc analysis was conducted to explore why patients undergoing RAI alone had a greater LRF compared with those undergoing both RAI and EBRT. To perform this analysis, treatment with RAI alone were compared (eTable 1 in the Supplement). Patients who did not receive routine care owing to patient factors (eg, patient refusal or contraindication to EBRT) or distant metastatic disease were excluded from this analysis because they received treatment deviating from the usual treatment protocols. In 10 patients receiving RAI alone owing to invasion into the RLN only, there was no evidence of locoregional failure at 5 years. In comparison, patients receiving RAI alone owing to minimal invasion into the tracheal perichondrium and/or the esophageal muscularis had a 5-year LRF rate of 49% (95% CI, 24% to 81%) ( Figure 2B ) with a difference in survival of 49% (95% CI, 20% to 71%). In these 6 locoregional failures, 2 patients had esophageal muscularis involvement only, 2 patients had tracheal perichondrium involvement only, and 2 patients had involvement of both the esophageal muscularis and the tracheal perichondrium. All patients were older than 45 years (range, 48-78 years).
Distant Metastatic Failure
Seventeen patients (19%) in the entire cohort had recurrent disease at a distant metastatic site. Of these recurrences, 7 (41%) were in patients undergoing RAI alone, and 10 (59%) were in patients undergoing both RAI and EBRT (effect size = 7%; 95% CI, −10% to 23%). Ten patients (59%) had distant metastasis in the lung only, 3 (18%) had bony metastasis only, 1 (6%) had a brain metastasis only, and 1 (5%) had a skull base metastasis. One patient (6%) had both lung and liver metastases, and 1 (5%) both lung and bony metastases. Five-year distant metastatic failure was 25% (95% CI, 12% to 48%) in those undergoing RAI alone and 23% (95% CI, 13% to 41%) in those undergoing both RAI and EBRT (effect size = −2%; 95% CI, −20% to 15%) ( Figure 2C ).
Predictors of Failure
Univariate and multivariate analyses for DFS are summarized in Table 3 
Discussion
This retrospective cohort study investigated the role of adjuvant treatment with RAI with or without EBRT following surgery in patients with T4a-differentiated thyroid cancer. Though patients receiving RAI and EBRT following surgery had more extensive soft tissue and visceral invasion, DFS, OS, and DSS were not different compared with those undergoing treatment with RAI alone. Patients treated with RAI alone demonstrated worse locoregional control compared with those undergoing both RAI and EBRT. Exploratory analysis showed that the addition of EBRT may be considered in patients with tracheal perichondrial invasion and/or esophageal muscularis involvement owing to worse locoregional control with treatment with RAI alone. Lastly, our study demonstrated that age and esophageal involvement were independent predictors of worse DFS. The purpose of adjuvant EBRT is to minimize risk of locoregional recurrence of differentiated thyroid cancer. 5, 12 However, the indications for EBRT are controversial. Our study, along with others, demonstrates improved locoregional control with EBRT compared with RAI alone. Lee et al 7 studied a similar cohort of patients with pT4a or pN1b papillary thyroid cancer. Like our study, no difference was found in overall survival or distant recurrence-free survival, but EBRT resulted in improved locoregional control. As well, treatment with RAI alone in these patients was an independent predictor of locoregional recurrence. Understanding specific indications for EBRT are limited owing to a lack of prospective clinical trials. Biermann et al 13 attempted a prospective trial but accrual in the randomization arm was less than expected, and no difference in recurrence was found between those receiving EBRT and those not receiving EBRT. As in our cohort, no difference was found in overall survival. However, because the accrual was low in the randomization arm, conclusions from the Biermann et al study must take into account that the majority of patients (316 of 351 [90%]) were assigned to a treatment group by the treatment physician, resulting in selection bias.
Though our study did not investigate adverse effects of radiotherapy, EBRT is not without complications. Though no long term grade 3 toxic effects were reported by Schuck et al, 14 patients experienced skin, mucosal, salivary, and swallowing issues. As well, EBRT was demonstrated to result in a significant reduction in head and neck radiation-specific quality of life. It should be emphasized all patients in our cohort undergoing treatment with RAI and EBRT had extensive soft tissue and visceral invasion, and use of EBRT as adjuvant treatment in differentiated thyroid cancer should be rare. Because EBRT limits future surgical options, use of EBRT at our institution is limited to patients in whom future surgery is either not an option, or such that total laryngectomy would be the only surgical option should disease recur. Therefore, in our cohort, patients undergoing en bloc resection of the trachea or esophagectomy were more likely to undergo EBRT and RAI because there is less tolerance for local recurrence in these patients. At our institution, we found that extensive soft tissue and visceral extension was the most common indication for use of both RAI and EBRT following surgery. These patients had multiple sites of gross extrathyroidal extension or intraluminal disease. On the contrary, patients with only RLN invasion did not routinely undergo EBRT. In our cohort, treatment with RAI alone in these patients demonstrated good disease control. In patients with minimal invasion into the tracheal perichondrium and/or the esophageal muscularis, survival did not decrease with treatment with RAI alone, but locoregional control was poor in this group. However, these findings were based on post hoc exploratory analysis and further investigation is required to quantify this relationship.
Age as a predictor of DFS is expected, as it is a wellknown risk factor for differentiated thyroid cancer and is incorporated into the American Joint Commission on Cancer Staging System. [15] [16] [17] Additionally, esophageal invasion was found to be an independent predictor of DFS in our study. Esophageal invasion is associated with tracheal invasion and A, Log-rank P = .01; B, log-rank P = .02; C, log-rank P = .57. EBRT indicates external beam radiotherapy; RAI, radioactive iodine; RLN, recurrent laryngeal nerve. for other disease factors. Thus, further investigation into the role of EBRT in controlling even minimal esophageal invasion is required.
Limitations
This study is limited by being a retrospective study. As with other retrospective studies, treatment decisions were made by clinicians and not randomized, which may introduce selection bias. Selection bias may be due to differences in the degree of invasion found at the time of surgery, as demonstrated by eTable 1 in the Supplement, and needs to be taken into consideration when interpreting these data. However, baseline characteristics in the groups are distributed equally between groups. Furthermore, though no difference was found between groups in DFS, OS, or DSS, this study was not powered to be a noninferiority study. Third, findings of increased LRF in patients with minimal esophageal and/or tracheal invasion were demonstrated on post hoc analysis and requires further investigation in order to make definitive conclusions. Nonetheless, this retrospective study demonstrates a detailed comparison of adjuvant treatment regimens in patients with locally aggressive differentiated thyroid cancer. This comparison is unique in that it included consideration of the location and degree of soft tissue and visceral invasion. The major findings echo those currently in the literature but also emphasize the need for further investigation into different disease behaviors in patients with different patterns of locally advanced differentiated thyroid cancer.
Conclusions
In locally advanced T4a-differentiated thyroid cancer, age and presence of esophageal invasion were independent predictors of poor disease control. The addition of EBRT to RAI resulted in good disease control in patients with extensive soft tissue and visceral extension. However, in patients undergoing adjuvant treatment with RAI alone, those with tracheal perichondrium and/or esophageal muscularis involvement only demonstrated worse locoregional control compared with patients with RLN invasion only. Thus, treatment with RAI alone may be adequate for patients with tumors demonstrating RLN invasion only. The role of adjuvant treatment RAI and EBRT should be further explored in patients with tracheal perichondrium and/or esophageal muscularis involvement only.
